Illumina (NASDAQ:ILMN) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Wednesday.

Several other research firms have also commented on ILMN. Citigroup increased their price objective on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, October 25th. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and increased their target price for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a research report on Friday, October 27th. Barclays increased their target price on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 25th. Finally, Argus increased their target price on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $201.98.

Illumina (NASDAQ:ILMN) traded up $0.69 during trading hours on Wednesday, reaching $214.67. 682,300 shares of the company’s stock traded hands, compared to its average volume of 955,885. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The stock has a market cap of $31,241.08, a price-to-earnings ratio of 62.57, a price-to-earnings-growth ratio of 3.53 and a beta of 0.79. Illumina has a 52-week low of $120.00 and a 52-week high of $230.72.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the business posted $0.97 EPS. analysts expect that Illumina will post 3.75 earnings per share for the current year.

In related news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total transaction of $4,222,200.00. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at approximately $113,825,445.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 166,150 shares of company stock worth $34,767,331. Corporate insiders own 0.89% of the company’s stock.

A number of large investors have recently modified their holdings of ILMN. Dupont Capital Management Corp purchased a new position in shares of Illumina in the third quarter valued at about $153,000. Advisory Services Network LLC increased its position in shares of Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Penserra Capital Management LLC increased its position in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the period. Paradigm Asset Management Co. LLC increased its position in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the period. Finally, West Coast Financial LLC purchased a new position in shares of Illumina in the third quarter valued at about $216,000. Institutional investors own 91.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/illumina-ilmn-rating-lowered-to-hold-at-bidaskclub/1752144.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.